|
Variables
|
Whole
|
CVs
|
Non-CVs
|
Pa
|
|---|
|
(n = 386)
|
(n = 92)
|
(n = 294)
|
|---|
|
Characteristics
|
|
Age (years)
|
72.7 ± 5.4
|
72.9 ±5.2
|
72.8 ± 5.5
|
0.568
|
|
Male
|
269/386 (69.7)
|
65/92 (70.6)
|
204/294 (69.4)
|
0.818
|
|
BMI (kg/m2)
|
23.6 ± 2.1
|
24.3 ± 2.3
|
23.4 ± 2.2
|
0.001
|
|
Cardiovascular disease risk factors
|
|
Hypertension
|
270/386 (69.9)
|
64/92 (69.6)
|
206/294 (70.1)
|
0.927
|
|
Dyslipidemia
|
246/386 (90.2)
|
83/92 (90.2)
|
265/294 (90.1)
|
0.982
|
|
Smoking, current or former
|
246/386 (63.7)
|
59/92 (64.1)
|
187/294 (63.6)
|
0.927
|
|
Family history
|
82/386 (21.2)
|
21/92 (22.8)
|
61/294 (20.7)
|
0.671
|
|
Medications
|
|
Calcium-channel blocker
|
165/386 (42.7)
|
48/92 (52.2)
|
117/294 (39.8)
|
0.036
|
|
ACEI
|
212/386 (54.9)
|
56/92 (60.9)
|
156/294 (53.1)
|
0.189
|
|
ARB
|
172/386 (14.8)
|
40/92 (43.5)
|
132/294 (44.9)
|
0.943
|
|
β-blocker
|
114/386 (44.5)
|
27/92 (29.3)
|
87/294 (29.6)
|
0.964
|
|
Aspirin
|
347/386 (89.9)
|
84/92 (91.3)
|
263/294 (89.5)
|
0.608
|
|
Insulin
|
27/386 (7.0)
|
12/92 (13.0)
|
15/294 (5.1)
|
0.009
|
|
Sulfonylurea
|
147/386 (40.0)
|
74/92 (80.0)
|
73/294 (25.0)
|
0.001
|
|
Metformin
|
38/386 (10.0)
|
9/92 (9.7)
|
29/294 (10.0)
|
0.999
|
|
α-Glucosidase inhibitor
|
127/386 (33.0)
|
54/92 (58.6)
|
73/294 (25.0)
|
0.001
|
|
Thiazolidine
|
69/386 (18.0)
|
49/92 (53.2)
|
20/294 (6.8)
|
0.001
|
|
Statin
|
224/386 (58.0)
|
47/92 (51.1)
|
162/294 (55.1)
|
0.501
|
- Data are presented as mean ± SD or the number and its percentage (%) percentage = the number of each individual category divided by n CVs, cardiovascular events; BMI: body mass index; ACEI: angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker
- aIndicates the comparison of mean or percentage between CVs group and non-CVs group
